Clinicopathological Profile and Receptor Status in Recurrent Breast Carcinoma
Abstract
Background: Breast carcinoma is one of the most common
malignancies worldwide, with approximately one million
new cases diagnosed annually. Estrogen receptor (ER),
progesterone receptor (PR), and human epidermal growth
factor receptor-2 (HER2) play a crucial role in determining
prognosis and guiding treatment strategies.
Objective: To assess the demographics, site and TNM staging
and the ER, PR, and HER-2 reactivity patterns in recurrent
breast carcinoma.